2024-511981-36-00招募中2 期
A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants with AATD Pi*ZZ on WVE-006 (RestorAATion-2)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- The proportion of participants with adverse events.
研究概览
简要总结
To evaluate the safety and tolerability of WVE-006 in participants with Pi*ZZ AATD
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Healthy as determined by the Investigator, based on a medical evaluation, or has mild to moderate AATD-induced lung disease (FEV1 ≥50%) and/or stable mild AATD-induced liver disease (≤F2 (≤10 kPa)) on FibroScan.
- •Genetic testing confirming Pi*ZZ.
- •Participant has been a non-smoker for at least 1 year prior to screening.
排除标准
- •Participant has a history of multiple drug allergies or of allergic reaction to an oligonucleotide or to N-acetylgalactosamine (GalNAc).
- •Donation of blood or blood products in excess of 500 mL within 12 weeks prior to Screening Visit and/or unwilling to refrain from blood donation for the duration of the study.
- •Participant has received an investigational agent within 3 months of the Screening Visit.
- •Participant has a history of intolerance or any medical condition that might interfere with subcutaneous injections.
- •Any ongoing or recent infections.
- •Any recent or planned vaccinations during the study.
- •Participant has a history of regular alcohol consumption exceeding 14 standard drinks/week.
- •Unwilling to abstain from alcohol for 48 hours prior to dosing at each of the dosing visits.
- •Any recent or planned major surgery during the study.
- •Participant has any medical condition or social circumstance that, in the opinion of the Investigator, would make the participant unsuitable for participation in the study or for dosing on Day 1, or could interfere with the assessments of safety, pharmacodynamics, or pharmacokinetics, or completion of the study.
- •Participant currently on AAT augmentation therapy, planned to be on augmentation therapy anytime during the study, or has been on augmentation therapy within 30 days prior to Screening Visit.
结局指标
主要结局
The proportion of participants with adverse events.
The proportion of participants with adverse events.
次要结局
- Single Ascending Dose - Change from baseline in levels of serum M-AAT protein.
- Multiple Ascending Dose - Change from baseline in levels of serum M-AAT protein
- Single Ascending Dose - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)
- Single Ascending Dose - Maximum concentration of WVE-006 in plasma
- Multiple Ascending Doses - Area under the plasma concentration time curve for WVE-006 from time of dosing to the last measurable concentration (AUClast)
- Multiple Ascending Doses - Maximum concentration of WVE-006 in plasma (Cmax)
研究者
Clinical Operations
Scientific
Wave Life Sciences Ireland Limited
研究点 (2)
Loading locations...
相似试验
招募中
2 期
A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and myelodysplastic syndrome with HOX gene overexpression2025-521299-76-00AstraZeneca AB1
招募中
2 期
A trial to learn how safe AZD4512 is and how it works in the bodies of people with B-cell acute lymphoblastic leukemia (B-ALL)2025-522372-93-00AstraZeneca AB13
招募中
2 期
A study to investigate WEF-001 in patients with Advanced KRAS-Mutant Solid Tumours.2024-518644-21-01Auricula Biosciences Inc.27
招募中
2 期
A Phase 2a Study of the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis2024-520201-39-00Odyssey Therapeutics Inc.47
招募中
2 期
A Phase IIb Two-Cohort, Randomised, Placebo controlled, Double blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Chronic Heart FailureChronic Heart Failure2023-510148-19-00AstraZeneca AB235